Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program — Lea Beier (2022) | RDL Network
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
Article 2022 en
Authors
LB
Lea Beier
SL
Shihai Lu
LF
Lionel Riou França
Abstract
1 min read
Over the past few years, data from phase III of GLORIA-AF show that OACs have become the standard treatment option, with most newly diagnosed AF patients prescribed a NOAC. However, in some regions a remarkable proportion of patients remain undertreated. In comparison with phase II, more patients received NOACs in phase III while the prescription of VKA decreased. VKAs were preferred over NOACs in patients with impaired kidney function.
Yang Liu, Steven Ho Man Lam, Giulio Francesco Romiti, Bi Huang, Yang Chen, Tze-Fan Chao, Brian Olshansky, Kui Hong, Menno V. Huisman, Professor Gregory Lip
Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, Christine Teutsch, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Chang Sheng, Kristina Zint, Amelie Elsaesser, Dorothee B. Bartels, Professor Gregory Lip, Dzifa Wosornu Abban, Nasser Abdul, Mark Abelson, Alan Ackermann, Fran Adams, Luthando Adams, Pedro Adragão, Walter Ageno, Rajesh Aggarwal, Sergio Agosti, Javier A. Marin, Francisco Aguilar, Julio Alberto Aguilar Linares,
Giulio Francesco Romiti, Bernadette Corica, Tommaso Bucci, Giuseppe Boriani, Brian Olshansky, Tze‐Fan Chao, Menno V. Huisman, Marco Proietti, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.